News >

NICE Recommends Ixazomib for Multiple Myeloma Through CDF

Jason Harris
Published: Tuesday, Dec 19, 2017

blood cells The United Kingdom's National Institute for Health and Care Excellence (NICE) has issued guidance recommending ixazomib (Ninlaro) in for patients with relapsed/refractory multiple myeloma.1

= .02). The median duration of response was 20.5 months with ixazomib versus 15.0 months in the control arm.


  1. Final appraisal determination: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. Updated December 19, 2017. Accessed December 19, 2017.
  2. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621-1634.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication